Health
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium","length":269,"tagName":"p"},{"type":"text","content":"Late-breaker abstract recently submitted to the Multinational Association of Supportive Care in Cancer (MASCC) shows additional significant results for breast cancer subgroup","length":174,"tagName":"p"},{"type":"text","content":"The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025, and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022","length":215,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / March 27, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") family company Napo Pharmaceuticals ("Napo") today announced that the U.S. Food and Drug Administration (FDA) has granted Napo a Type C Meeting in the second quarter of 2025 to discuss the responder analysis in the prespecified subgroup of patients with breast cancer for crofelemer in Napo's Phase 3 OnTarget trial. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy. The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025,1 and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022.2","length":940,"tagName":"p"},{"type":"text","content":"Napo recently submitted a late-breaker abstract to MASCC on additional significant results in adult breast cancer patients from the OnTarget study for consideration for presentation at MASCC's June 26-28, 2025 Annual Meeting in Seattle, Washington. The authors include Pravin Chaturvedi, PhD, who is Jaguar's Chief Scientific Officer and Chair of Napo's Scientific Advisory Board, as well as leading oncologists and cancer patient advocates.","length":453,"tagName":"p"},{"type":"text","content":""As a cancer patient, having optio...